Antisense Therapeutics Starts dosing monkeys in ATL1102 toxicology study
- Antisense Therapeutics (ANP) commences the dosing stage of a nine-month chronic monkey toxicology study of its ATL1102 treatment in the US
- The toxicology study is expected to support the advancement of ATL1102 for the potential treatment of Duchenne muscular dystrophy (DMD)
- Antisense says the completion of the toxicology study should be the final requisite step for the US FDA to allow dosing of the product for a term longer than six months
- The study should complete animal dosing by November this year, with results to be released in the first half of 2024
- ANP shares are down 4.26 per cent and trading at nine cents at 12:23 pm AEDT
